{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-073304","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.538090+00:00","generated_at":"2026-05-17T21:41:16.684365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IDEXX Q2 EPS $3.63 (+49% reported); raises FY2025 revenue and EPS guidance","bullets":["Q2 revenue $1,109M (+11% reported, +9% organic); CAG Diagnostics recurring revenue +9% reported, +7% organic.","Record quarterly instrument placements including nearly 2,400 IDEXX inVue Dx units.","FY2025 revenue guidance raised to $4,205M-$4,280M (prior $4,095M-$4,210M); organic growth outlook 7.0%-9.0%.","FY2025 EPS guidance raised to $12.40-$12.76 (prior $11.93-$12.43); reported growth 16%-20%.","Operating margin guidance improved to 31.3%-31.6%; comparable expansion 50-80 bps."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-073304","json":"https://secwatch.observer/filing/0001104659-25-073304.json","markdown":"https://secwatch.observer/filing/0001104659-25-073304.md","text":"https://secwatch.observer/filing/0001104659-25-073304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000110465925073304/0001104659-25-073304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000110465925073304/tm2522386d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:41:16.684365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}